Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

Novartis NOVN-0.15%decrease; red down pointing triangle raised its guidance for the third time this year after higher third-quarter results topped expectations, boosted by revenue from its ...

which allows drugmakers to get their generic medicines approved for one or several—but not all—approved indications of their brand-name counterparts. Novartis disagrees with the decision and ...

With their headquarters in next year’s Host City, it’s great to have Novartis, a global leader in healthcare, supporting the ...

California VC firm Aditum Bio is reaching across the Pacific to hatch a brand-new biotech. Teaming up with China ... Jimenez ...

Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on the business.

During the trial, patients treated with Fabhalta experienced a significant reduction in proteinuria as early as two weeks.

Good morning and good afternoon, and welcome to the Novartis Q3 2024 Results Release ... And let's go through each one of these brands in more detail. So, moving to slide six, Entresto's sales ...